Table 1.

Inclusion criteria for the review on values and preferences for injectable pre‐exposure prophylaxis (PrEP)

Criteria	Eligibility
Article type	a. Published in peer‐reviewed journal between 1 January 2010 and 27 September 2021; OR
	b. Presented as abstract at a scientific conference between January 2010 and September 2021; OR
	c. Unpublished work containing relevant data
Intervention	Studies reporting primary data on injectable PrEP, including CAB‐LA, placebo products or hypothetical injectable PrEP use
Study population	a. Populations at substantial risk of HIV acquisition; OR
	b. Healthcare workers/stakeholders involved in any aspect of provision of injectable PrEP
Study design	a. Qualitative studies, including in‐depth interviews or focus group discussions; OR
	b. Experimental or non‐experimental studies quantitatively evaluating the use of injectable PrEP to prevent HIV among people at substantial risk of HIV infection
Key outcomes	a. Awareness of injectable PrEP
	b. Values and preferences related to injectable PrEP
	c. Feasibility a , acceptability b or satisfaction c with injectable PrEP
	d. Concerns regarding injectable PrEP
	e. Willingness to use injectable PrEP
	f. Barriers and facilitators of injectable PrEP use

^a Feasibility is defined as “the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting” [23, 24].

^b Acceptability is defined as “a multi‐faceted construct that reflects the extent to which people delivering or receiving a healthcare intervention consider it to be appropriate, based on anticipated or experienced cognitive and emotional responses to the intervention” [25].

^c Satisfaction is “the state of being content or fulfilled with a service or intervention based on one's needs and desires or being content with the general service‐delivery experience” [26]. Abbreviations: PrEP, pre‐exposure prophylaxis; CAB‐LA, long‐acting injectable cabotegravir.